Spero Therapeutics at guggenheim conference: SP001 drives next phase
At a glance
- $SPRO today−4.77%last $0.90
- Vs industry peers−3.91 pts6-peer median −0.85% · far behind
- Since Nov 10−13.3%from the first trade after the story
- 52-week range2.4% above low$0.88 – $3.08
- Cash runway~2.5 yrs$107.9M cash ÷ $3.6M/mo burn · 10-Q
- Coverage1 this week2 in 30 days · too few stories to call a pace
- Key person: Filed with SEC
- Clear: legal, regulatory, security, operational, financial integrity
Early signals (2) — filed with the SEC or first reported, not yet widely covered
- Key person · SEC 8-K, Item 5.02, Nov 10: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
- Key person · SEC 8-K, Item 5.02, Oct 27: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.
What it means
- What to watch: Drugmakers are judged by their pipelines — late-stage trials carry more weight than quarterly earnings, especially when the future is uncertain.
- How the stock is trading: $SPRO -4.77% in the latest session.
- Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Where the stock stands
Spero Therapeutics ($SPRO) fell 4.77% to $0.90 in the latest session. Over the past month it is down 19.5%. That leaves it 71% below its 52-week high of $3.08 and 2.4% above its low of $0.88, close to the bottom of its range. It has been a volatile year: the high was 3.5 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 12, 2026), $SPRO lost $44.3M over the quarter to Sep 30, 2026. Operations used $32.1M of cash over the nine months to Sep 30, 2026 — about $3.6M a month — against $107.9M in cash on Sep 30, 2026. At that pace the cash covers about 2.5 years. Total liabilities were $109.2M against $107.9M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 10, the same day as this story; it is $SPRO's own account and the first thing to read. Figures are as filed with the SEC; the $SPRO page has the full statements.
How much coverage it is getting
This is one of 2 stories on Spero Therapeutics in Wook's last 30 days of coverage, including 1 this week. Its 30-day average is less than one a week, so this week is well above its usual pace. Going by their wording, 0 read bullish, 1 neutral and 1 bearish. This one reads neutral too, in line with most of them. This is the only one from Investing.com; the rest came from other outlets.
The bigger picture
Healthcare stocks swing on FDA decisions, trial results, and pricing changes — one event can shift a drugmaker's fate, while broader policy shifts affect the whole sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The $SPRO page includes full charts, filings, and a valuation model for deeper insight. Comparing coverage from different outlets helps spot confirmation or repetition. Wook AI can fetch live data and run analysis on demand.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 10, 2026. $SPRO has moved -13.25% ($1.04 to $0.90). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
